Samsung Biologics Signs MOU with Sartorius to Enhance Supply Chain for Biomedicines
The agreement follows a recent announcement that Sartorius plans to invest $100 million in Songdo, South Korea’s bio cluster.
Samsung Biologics has signed a memorandum of understanding (MOU) with Sartorius to further strengthen the supply chain for biomedicines. The MOU follows a recent announcement by Sartorius that the company plans to invest $100 million in South Korea's bio cluster, Songdo, to build a bioprocess manufacturing facility for equipment and materials, Samsung Biologics announced in a Nov. 16, 2020 press release.
Sartorius plans to supply materials such as disposable bags, cell culture media, and filters to Samsung Biologics. The facility will be built on a 24,333-m2 site in Songdo. Construction is expected to be completed by 2022.
Source: Samsung Biologics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
